RT Journal Article
T1 Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
A1 Perez, Ana Belen
A1 Chueca, Natalia
A1 Macias, Juan
A1 Pineda, Juan Antonio
A1 Salmeron, Javier
A1 Rivero-Juarez, Antonio
A1 Hidalgo-Tenorio, Carmen
A1 Espinosa, Maria Dolores
A1 Tellez, Francisco
A1 Von-Wichmann, Miguel Angel
A1 Omar, Mohamed
A1 Santos, Jesus
A1 Hernandez-Quero, Jose
A1 Anton, Jose Joaquin
A1 Collado, Antonio
A1 Lozano, Ana Belen
A1 Garcia-Deltoro, Miguel
A1 Casado, Marta
A1 Pascasio, Juan Manuel
A1 Selfa, Aida
A1 Rosales, Jose Miguel
A1 De la Iglesia, Alberto
A1 Arenas, Juan Ignacio
A1 Garcia-Bujalance, Silvia
A1 Rios, Maria Jose
A1 Bernal, Enrique
A1 Martinez, Onofre
A1 Garcia-Herola, Antonio
A1 Velez, Monica
A1 Rincon, Pilar
A1 Garcia, Federico
K1 Área de Gestión Sanitaria Sur de Granada
K1 Área de Gestión Sanitaria Sur de Sevilla
K1 Amides
K1 Antiviral agents
K1 Benzofurans
K1 Carbamates
K1 Cyclopropanes
K1 Drug resistance, viral
AB Treatment guidelines differ in their recommendation to determine baseline resistance associated substitutions (RAS) before starting a first-line treatment with direct-acting antivirals (DAAs). Here we analyze the efficacy of DAA treatment with baseline RAS information. We conducted a prospective study involving 23 centers collaborating in the GEHEP-004 DAA resistance cohort. Baseline NS5A and NS3 RASs were studied by Sanger sequencing. After issuing a comprehensive resistance report, the treating physician decided the therapy, duration and ribavirin use. Sustained virological response (SVR12) data are available in 275 patients. Baseline NS5A RAS prevalence was between 4.3% and 26.8% according to genotype, and NS3 RASs prevalence (GT1a) was 6.3%. Overall, SVR12 was 97.8%. Amongst HCV-GT1a patients, 75.0% had >800,000 IU/ml and most of those that started grazoprevir/elbasvir were treated for 12 weeks. In genotype 3, NS5A Y93H was detected in 9 patients. 42.8% of the HCV-GT3 patients that started sofosbuvir/velpatasvir included ribavirin, although only 14.7% carried Y93H. The efficacy of baseline resistance-guided treatment in our cohort has been high across the most prevalent HCV genotypes in Spain. The duration of the grazoprevir/elbasvir treatment adhered mostly to AASLD/IDSA recommendations. In cirrhotic patients infected with GT-3 there has been a high use of ribavirin.
PB Public Library of Science
YR 2019
FD 2019-08-01
LK http://hdl.handle.net/10668/14460
UL http://hdl.handle.net/10668/14460
LA en
NO Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, et al. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One. 2019 Aug 30;14(8):e0221231
DS RISalud
RD Apr 12, 2025